HealthMyne’s radiomic and quantitative imaging solution was used in a lung carcinoma study that was published in Cancer Control, the company announced recently. According to a release, the study demonstrated HealthMyne’s…
Cellectar Biosciences has received another patent by the Japanese Patent Office, this time for its proprietary phospholipid-ether (PLE), the company announced today. According to a release, the patent provides composition…
NorthStar Medical Radioisotopes and Ion Beam Applications (IBA), a provider of proton therapy solutions for the treatment of cancer, expanded its collaboration to increase the global availability of technetium-99m (Tc-99m),…
NorthStar Medical Radioisotopes is making organizational changes to drive focused growth for its therapeutic and specialized single photon emission computed tomography (SPECT) radioisotopes business, the company announced today. “NorthStar is…
Exact Sciences has acquired Ashion Analytics to help accelerate the development of its precision oncology portfolio, including minimal residual disease (MRD) and other sequencing-based tests, the company announced recently. According…
The Promega Wellness Center, a healthcare facility for employees on the company’s Fitchburg, Wis., campus, is now a state-approved COVID-19 vaccination site, the company announced today. “Public-private partnerships are critical…
The European Commission has granted Cellectar Biosciences orphan drug designation and 10 years of European market exclusivity for CLR 131 in Waldenstrom’s Macroglobulinemia (WM), the company announced today. “Receipt of European orphan…
Cellectar Biosciences has started a trial for CLR 131 in Waldenstrom’s macroglobulinemia (WM), the company announced recently. According to a release, the trial will include 50 WM patients who will…
NorthStar Medical Radioisotopes received approval from the U.S. Food and Drug Administration (FDA) to produce the isotope Molybdenum-99 (Mo-99) from concentrated Mo-98 (cMo-98), the company announced recently. “This approval of production…
Cellectar Biosciences announced today the pricing of its underwritten public offering of its common stock at $1.35 per share, which will result in gross proceeds of approximately $24.5 million. Cellectar also…
